MedPath

To evaluate the Efficacy of Punica Granatum in Promotion of Cardiovascular Health

Phase 3
Conditions
Health Condition 1: I998- Other disorder of circulatory system
Registration Number
CTRI/2022/03/040868
Lead Sponsor
CSIR
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients who are willing to undergo for the treatment.

Age between 20 -70 years.

Pre-hypertensive patients (as per JNC VII Criteria) and impaired lipid profile.

Exclusion Criteria

Hypertensive patients (SBP>=140mm of Hg and/or DBP>=90mm of Hg).

Patients with FBS >150mg/dl; PPBS > 200mg/dl; RBS > 250mg/dl.

Subjects with established diagnosis of CAD requiring any procedure in next 6 months â?? angioplasty or bypass surgery or subjects with New York Heart Association (NYHA) Classification Category III and IV cardiac insufficiency, or any other clinically significant cardiovascular disease.

Subjects with Haemoglobin percentage < 9 gm% for males and <8gm% for females.

Patients suffering from major systemic illness necessitating long term treatment (R.A., PTB, malignancy etc.).

Subjects with concurrent Hepatic Dysfunction (defined as AST and/or ALT > 3 times of the upper normal limit)

Subject on systemic or oral steroids, oral contraceptive pills or estrogens replacement therapy.

Any other condition which the Investigator thinks may compromise the safety of the subject.

Pregnant/ lactating women.

Patients who have participated in any clinical trial during past 6 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in Hs-CRP from 1st day i.e. baseline to 12th week. <br/ ><br>Change in functional capacity from 1st day i.e. baseline to 12th week. <br/ ><br>Change in S. Lipid profile from 1st day i.e. baseline to 12th week. <br/ ><br>Change in blood Pressure from 1st day i.e. baseline to 12th week.Timepoint: 84 days
Secondary Outcome Measures
NameTimeMethod
Change in FBS and HbA1c from 1st day i.e. baseline to 12th week. <br/ ><br>Change in Heart Rate from 1st day i.e. baseline to 12th week. <br/ ><br>Change in weight and BMI from 1st day i.e. baseline to 12th week. <br/ ><br>Change in SF-36 health survey score from 1st day i.e. baseline to 12th week.Timepoint: 12 weeks
© Copyright 2025. All Rights Reserved by MedPath